foxo4-dri senolytic or senomorphic (Proxofim) 10mg*10 vials - Nexus peptides FOXO4-DRI Dosing: 1mg Senolytic Protocol
FOXO4 DRI Dosing: 1mg Senolytic Protocol (2026) Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Cleara Biotech senolytic candidate FOXO4 DRI The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity.
Pay in 4 interest-free payments of $7.15 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11


